Ankyra Therapeutics
Chief Process & Manufacturing Officer
Dr. Greg Zarbis-Papastoitsis is the Chief Process & Manufacturing Officer at Ankyra Therapeutics, an immuno-oncology company. Ankyra is in Phase 1 clinical trials with an intratumoral anchored cytokine. He was a scientific advisor to 4th Dimension Bioprocess focusing on continuous manufacturing, which joined National Resilience Inc., in December 2020. He was the EVP of Process and Manufacturing at Compass Therapeutics managing all CMC functions. Compass is developing a comprehensive portfolio of biotherapeutics to combat Cancer and Autoimmune diseases. While at Compass he lead the development of an anti-CD137 antibody currently in Phase 1/2 clinical trials for solid tumors. Previously he was the SVP of Process and Manufacturing Sciences at Eleven Biotherapeutics. His group developed and transfered processes for GMP production including Isunakinra, EBI-005, an IL-1 inhibitor, which was in Phase 3 clinical studies for Dry Eye Disease and Allergic Conjunctivitis, and EBI-031, an anti-IL6 antibody, for treating Macular Edema. Eleven filled an IND with EBI-031 in June 2016. Before Eleven he was the Senior Director of Downstream and Analytical Development at PERCIVIA, LLC, developing technologies for proteins produced with the PER.C6® cell line. Previously he was Associate Director of Process Development and Analytics at Syntonix Pharmaceuticals. At Syntonix, Dr. Zarbis-Papastoitsis was responsible for the process development of pre-clinical and early clinical programs including a long lasting Factor IX (ALPROLIX®). Biogen Idec aquired Syntonix in December 2006. Prior to Syntonix Dr. Zarbis-Papastoitsis spent several years with organizations such as Repligen, Seragen (worked on the purification development of IL2-Diptheria Toxin (ONTAK®)), Millennium Pharmaceuticals (worked on an anti-PSMA ADC that entered Phase 1 clinical trials), and Abbott Biologics involved in preclinical, clinical, and commercial stage programs. At Abbott he was one of the key scientists that designed the second-generation commercial process for HUMIRA®, a monoclonal antibody against Rheumatoid Arthritis and other autoimmune diseases. Dr. Zarbis-Papastoitsis received his B.S. in Biochemistry at the State University of New York at Binghamton, where he also received a PhD degree. During his graduate studies he elucidated proteolytic activities in germinating soybean seeds. He then did 3 years of post-doctoral studies at Boston University School of Medicine investigating proteases in Alzheimer disease